<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Niger Med J</journal-id><journal-id journal-id-type="iso-abbrev">Niger Med J</journal-id><journal-id journal-id-type="publisher-id">NMJ</journal-id><journal-title-group><journal-title>Nigerian Medical Journal : Journal of the Nigeria Medical Association</journal-title></journal-title-group><issn pub-type="ppub">0300-1652</issn><issn pub-type="epub">2229-774X</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29269983</article-id><article-id pub-id-type="pmc">5726175</article-id><article-id pub-id-type="publisher-id">NMJ-58-63</article-id><article-id pub-id-type="doi">10.4103/0300-1652.219348</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of atorvastatin on proteinuria of type 2 diabetic nephropathy in patients with history of gestational diabetes mellitus: A clinical study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Abbasalizadeh</surname><given-names>Fatemeh</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Saleh</surname><given-names>Parviz</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Dousti</surname><given-names>Rana</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Piri</surname><given-names>Reza</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib><contrib contrib-type="author"><name><surname>Naghavi-Behzad</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff5">4</xref></contrib><contrib contrib-type="author"><name><surname>Abbasalizadeh</surname><given-names>Shamsi</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1">Department of Gynecology and Obstetrics, Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="aff2"><label>1</label>Chronic Kidney Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="aff3"><label>2</label>Department of Nursing and Midwifery, Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="aff4"><label>3</label>Medical Philosophy and History Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="aff5"><label>4</label>Students' Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Shamsi Abbasalizadeh, Department of Gynecology and Obstetrics, Women's Reproductive Health Research Center, Tabriz University of Medical Science, Daneshgah Street, Tabriz, Eastern Azerbaijan, Iran. E-mail: <email xlink:href="sabbasalizadeh@yahoo.com">sabbasalizadeh@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2017</year></pub-date><volume>58</volume><issue>2</issue><fpage>63</fpage><lpage>67</lpage><permissions><copyright-statement>Copyright: &#x000a9; 2017 Nigerian Medical Journal</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Gestational diabetes is known as one of the diseases through pregnancy. In the present study, changes in proteinuria after atorvastatin administration among patients with history of gestational diabetes were studied.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>In this randomized clinical trial, 42 patients were included in the study. Atorvastatin was administered for 21 patients, and 21 patients were designated as control group. Lipid profile, protein, and 24 h urine creatinine (uCr) levels were determined in the beginning and 3 months after intervention. <italic>P</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec><sec id="st3"><title>Results:</title><p>Lipid profile in intervention group was enhanced; low-density lipoprotein (LDL) had decreased while triglyceride had not changed and high-density lipoprotein had been increased. There was no statistically significant change in serum Cr, serum urea, estimated glomerular filtration rate, uCr, urine volume, 24-h urine protein level, or urine protein/Cr ratio on both groups during the study; also, there was no statistically significant difference between groups.</p></sec><sec id="st4"><title>Conclusions:</title><p>Although LDL level decreased after atorvastatin therapy, atorvastatin therapy had no effect on the level of proteinuria or other parameters related to kidney function.</p></sec></abstract><kwd-group><title>Key words</title><kwd>Atorvastatin</kwd><kwd>gestational diabetes</kwd><kwd>nephropathy</kwd><kwd>proteinuria</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Gestational diabetes, which is defined as impaired tolerance to glucose, is a known risk factor for type 2 diabetes mellitus (DM) and always gynecologists and endocrinologists have tried to control it. Although most of the gestational diabetes cases undergo a remission after delivery, some patients do not. Nephropathy in diabetic patients is defined by hypertension, albuminuria, and a decline in glomerular filtration rate (GFR).<xref rid="ref1" ref-type="bibr">1</xref> This is induced by prolonged glomerular hyperfiltration accompanying progressive increase in protein excretion induced by diabetic state. Leading cause of end-stage renal disease in many countries is diabetes.<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref> Estimated prevalence of diabetes in the world is about 6.5% and also it has been declared that there will be a 69% increase in numbers of people with diabetes in developing countries and a 20% increase in developed countries.<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref> Hence, preventing diabetic nephropathy has always been a field of interest for clinicians and researchers.</p><p>Glomerulosclerosis is the main event in the pathogenesis of diabetic nephropathy.<xref rid="ref7" ref-type="bibr">7</xref> Dyslipidemia and hyperinflammatory status and increased oxidative stress are of the factors contributed to the progression of glomerulosclerosis.<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref> Dyslipidemia as a contributing factor contributing in diabetic nephropathy is present in many patients with type 2 diabetes, and it has been a goal of therapy to subside progression of glumerosclerosis.<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref></p><p>3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor agents (statins) are one of the most common and used medications for dyslipidemia.<xref rid="ref15" ref-type="bibr">15</xref> In addition, it has been already shown that statins reduce both total mortality and cardiovascular mortality in patients without end-stage renal diseases.<xref rid="ref16" ref-type="bibr">16</xref> In a study, it was shown that statins do not affect renal function as measured by creatinine (Cr) clearance but reduces protein excretion in urine among patients with chronic renal diseases; meanwhile, statins are proved to be safe among these patients.<xref rid="ref17" ref-type="bibr">17</xref><xref rid="ref18" ref-type="bibr">18</xref><xref rid="ref19" ref-type="bibr">19</xref> In another study, systematic review of 27 randomized trials suggested that statins reduce the rate of kidney function loss by 1.2 ml/min/year.<xref rid="ref20" ref-type="bibr">20</xref> Another study had concluded that statins reduce albuminuria by 47% in people with &#x0003e;300 mg/24 h of albumin excretion at baseline. However, statins did not significantly influence urinary albumin excretion when baseline levels were &#x0003c;30 mg/24 h.<xref rid="ref21" ref-type="bibr">21</xref></p><p>Considering this issue, in the present study, effect of atorvastatin as a well-known statin was investigated in patients with diabetic nephropathy with history of gestational diabetes by examining proteinuria and renal function.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><sec id="sec2-1"><title>Patients and settings</title><p>The current study was conducted in Educational-Medical Centers of Tabriz University of Medical Sciences (Tabriz, Iran) from January 2014 to January 2016. After primary laboratory and clinical evaluations, 50 women with documented type 2 diabetic nephropathy and history of gestational diabetes were included in the study. Then, patients who were 20&#x02013;65 years old with type 2 DM and proteinuria levels lower than &#x0003c;3 g/d (nephrotic range) and estimated GFR (eGFR) &#x0003e;30 mL/min/1.73 m<sup>2</sup> (as calculated by the Modification of Diet in Renal Disease [MDRD] formula) were also included in the study.<xref rid="ref22" ref-type="bibr">22</xref> Informed consent was filled by participants, which was approved by the Tabriz University of Medical Sciences Ethics Committee; also, this consent was in compliance with the Helsinki Declaration. This study was registered in Iranian Registry of Clinical Trials(IRCT2016100918946N4).</p><p>Diabetic states of patients were controlled using insulin injection or oral anti-diabetic agents. Blood pressure was controlled using angiotensin receptor blockers and/or angiotensin-converting enzyme inhibitors and diuretics when needed, and blood pressure was kept &#x0003c;130/90 mmHg. All participants were under provision of a nutrition consultant and maintained a regular low-protein diet. Exclusion criteria included the use of fibrates, statins antagonists, aspirin, allopurinol, &#x003b2;-blockers, pentoxifylline, fish oil, other antioxidant drugs consumption in the past 6 months, active smoking, active coronary artery disease in the previous 6 months, diabetic foot, hepatitis, and poorly controlled diabetes (HbA1c &#x0003e;7.5%).</p><p>Finally, data from 50 patients with type 2 diabetic nephropathy and history of gestational diabetes were analyzed in this study (power 0.80 and significance 0.05), while eight were excluded from the study due to the uncooperativeness (four patients), Vitamin C intake during the intervention period (one patient), smoking during the intervention period (one patient), and development of end-stage renal disease (two patients). Using RandList software (version 1.2, DatInf GmbH, Tubingen, Germany), patients were divided into two groups randomly: one group receiving atorvastatin and the other group receiving placebo.</p></sec><sec id="sec2-2"><title>Study protocol</title><p>Atorvastatin 10 mg (Atorva<sup>&#x000a9;</sup>, NJ, USA) per day was administered to the patients in intervention group for 90 days. At the end of the 3<sup>rd</sup> month, the patients were asked to stop atorvastatin intake for a month. Meanwhile, for control group, exact protocol was administered using placebo instead of atorvastatin. Laboratory tests including lipid profile and uric acid level were performed in two stages: before intervention (baseline) and 90 days after intervention (91<sup>st</sup> day).</p></sec><sec id="sec2-3"><title>Blood sampling</title><p>Blood samples were obtained after 8 h of fasting in the morning before breakfast in sterile tubes. Then, they were centrifuged at 3000 rpm for 10 min at 4&#x000b0;C and then stored at &#x02212;79&#x000b0;C until assayed.</p></sec><sec id="sec2-4"><title>Laboratory analysis</title><p>Serum levels of fasting blood sugar (FBS), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), and triglyceride were determined using an automated chemical analyzer (Abbott analyzer, Abbott Laboratories, Abbott Park, Chicago, IL, USA). Then, low-density lipoprotein cholesterol (LDL-C) levels were calculated using the Friedewald equation.<xref rid="ref23" ref-type="bibr">23</xref></p><p>Jaffe method and glutamate dehydrogenase were used to calculate serum Cr (sCr) and urea levels, respectively.<xref rid="ref24" ref-type="bibr">24</xref><xref rid="ref25" ref-type="bibr">25</xref> Twenty-four hour urine samples were collected, and Cr and protein levels were assessed using colorimetric and immunoturbidimetric methods. eGFR was calculated using the MDRD formula.<xref rid="ref22" ref-type="bibr">22</xref></p></sec><sec id="sec2-5"><title>Statistical analyses</title><p>Statistical analyses were performed using the SPSS software package version 16 (SPSS Inc., IL, USA). The results are presented as mean &#x000b1; standard deviation. Distribution of variables was determined by Skewness, Kurtosis, and Kolmogorov&#x02013;Smirnov Z-tests. General linear model repeated measures analysis, paired sample <italic>t</italic>- test, or Mann&#x02013;Whitney U-test was used to assess the differences between each of the two stages, as appropriate. <italic>P</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>The mean age of the participants was 57.64 &#x000b1; 7.33 years in intervention group (45&#x02013;68 years) and 58.88 &#x000b1; 6.39 years in control group (45&#x02013;68 years). The mean duration of DM was 9.76 &#x000b1; 3.11 years (5&#x02013;15 years) in intervention group and 8.89 &#x000b1; 4.21 years in control group. The mean systolic and diastolic blood pressures at the beginning of the study were 121.68 &#x000b1; 10.12 mmHg and 77.86 &#x000b1; 4.12 mmHg in intervention group and 125.66 &#x000b1; 12.52 mmHg and 75.65 &#x000b1; 5.49 mmHg, in control group, respectively. These differences between two groups were not statistically significant.</p><p>Measured FBS and lipid profile in both groups are shown in <xref ref-type="table" rid="T1">Table 1</xref>; TC and LDL-C levels were reduced in intervention group statistically significant, and HDL-C after the intervention was increased statistically significant; also, this difference was statistically significant when it was compared to control group. These changes in control group were not seen. A comparison of baseline sCr, urea, eGFR, 24-h urine protein level, urine Cr (uCr), and protein/Cr ratio and values in 90<sup>th</sup> day is shown in <xref ref-type="table" rid="T2">Table 2</xref>. Subsequent analysis did not show any significant change during this period in both groups.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Changes in fasting blood glucose and lipid profile; a comparison between baseline and 90<sup>th</sup> day values in both groups</p></caption><graphic xlink:href="NMJ-58-63-g001"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Changes in serum creatinine, serum urea, estimated glomerular filtration rate, urine creatinine, urine volume, 24-h urine protein level, and urine protein/creatinine ratio; a comparison between baseline and 90<sup>th</sup> day values in both groups</p></caption><graphic xlink:href="NMJ-58-63-g002"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>In the present study, although there was a significant reduction in TC and LDL-C, as well as a statistically significant increase in HDL-C, no other statistically significant changes in FPG, sCr, serum Urea, eGFR, uCr, urine volume, 24-h urine protein level, or urine protein/Cr ratio were detected after atorvastatin therapy period.</p><p>Based on the present study, there is a controversy in results about urinary protein excretion levels and statin therapy in different studies. In the present study, there is no effect of atorvastatin therapy on urinary albumin excretion levels, in contrast to previous researches.</p><p>In a study by Nakamura <italic>et al</italic>., normotensive type 2 DM with microalbuminuria and dyslipidemia were treated with cerivastatin therapy which was associated with a significant reduction in urinary albumin excretion.<xref rid="ref26" ref-type="bibr">26</xref> In another study by Tonolo <italic>et al</italic>., administering simvastatin therapy on normotensive microalbuminuric hypercholesterolemic type 2 diabetic patients, urinary albumin excretion rate compared to the basal rate had decreased about 25%.<xref rid="ref27" ref-type="bibr">27</xref> Interestingly, in a study by Atthobari <italic>et al</italic>., pravastatin was reported not only to have no significant reduction in urinary albumin excretion but also to rise in urinary albumin excretion, particularly in the patients who received statins for a longer amount of time and in higher doses.<xref rid="ref28" ref-type="bibr">28</xref> In contrast to mentioned clinical findings supporting the role of statins reducing the urinary albumin excretion, a study by Campese <italic>et al</italic>. concluded that statins have the potential to inhibit albumin uptake by the human proximal nephron, as a result of the inhibition of HMG-CoA reductase in the proximal tubule cells.<xref rid="ref29" ref-type="bibr">29</xref></p><p>Although statin use is associated with an increase in protein excretion, it has been proved that the application of statins may lead to decreased inflammation, improved endothelial dysfunction, and inhibition of tubulointerstitial fibrosis.<xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref30" ref-type="bibr">30</xref><xref rid="ref31" ref-type="bibr">31</xref> In addition, duration of statin therapy is proposed as a factor that may influence the proteinuria level changes; in a study by D'Amico on patients with chronic kidney disease, following atorvastatin therapy, proteinuria was significantly reduced starting at the 6<sup>th</sup> month.<xref rid="ref32" ref-type="bibr">32</xref> In the present study, atorvastatin therapy was used in a short-term method.</p><p>According to results of the present study, short-term atorvastatin therapy in patients with type 2 diabetes with history of gestational diabetes has no significant influence on eGFR. Similarly, in a study by Tonolo <italic>et al</italic>., simvastatin therapy in type 2 diabetic patients for 1 year showed no significant change in eGFR.<xref rid="ref27" ref-type="bibr">27</xref> In a large-scale, long-term, prospective postmarketing surveillance study of hypercholesterolemic patients treated with pitavastatin, an increase in eGFR was noted after 104 weeks of statin therapy.<xref rid="ref33" ref-type="bibr">33</xref> In the present study, we did not observe any significant change in our studied patients' proteinuria or eGFR after short-term atorvastatin therapy.</p><p>In the present study, extremely strict criteria for patient selection were designated. Hence, our patients at the start of the study had uniform clinical characteristics. As the first study of its kind in Iran, our study on the effects of lovastatin on the renal function of patients with type 2 DM showed that this low-cost statin has no negative effect on renal function, eGFR, and proteinuria. Our results may be of particular importance to the patients in developing countries with a limited budget and for whom more potent and newer products of statins are not obtainable. Although no renoprotective effect of lovastatin on proteinuria and eGFR in type 2 diabetic patients with history of gestational diabetes was observed in this research, no damaging and destructive effect on renal function was revealed either.</p><p>Unfortunately, in the present study, dose titration for patients receiving atorvastatin was not performed; this may lead to proteinuria levels as some studies have highlighted the dose titration effect on their patients.<xref rid="ref34" ref-type="bibr">34</xref> Based on former studies, taking angiotensin-converting enzyme inhibitor or angiotensin receptor blocker drugs for blood pressure control or renoprotection in type 2 DM cases may influence the pure effect of statins on renal function.<xref rid="ref33" ref-type="bibr">33</xref> No differentiation of patients in terms of who does or does not receive this class of drugs was performed.</p><p>Finally, although proteinuria is at possible with all inhibitors of HMG-CoA reductase at some concentration, it is more likely to be seen with statins that are more potent inhibitors of HMG-CoA reductase.<xref rid="ref35" ref-type="bibr">35</xref><xref rid="ref36" ref-type="bibr">36</xref></p></sec><sec sec-type="conclusions" id="sec1-5"><title>CONCLUSIONS</title><p>Short-term atorvastatin therapy did not show any change in proteinuria or eGFR levels in patients with type 2 diabetes with history of gestational diabetes. In other words, atorvastatin may be prescribed with safety for patients with type 2 diabetes with a history of gestational diabetes with the risk of renal problems and definite indication for statin therapy.</p><sec id="sec2-6"><title>Financial support and sponsorship</title><p>This study was supported by the Tabriz University of Medical Sciences.</p></sec><sec id="sec2-7" sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>YM</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>LF</given-names></name></person-group><article-title>Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy</article-title><source>Biochem Biophys Res Commun</source><year>2013</year><volume>433</volume><fpage>359</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">23541575</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>F</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>XF</given-names></name><name><surname>Yu</surname><given-names>XQ</given-names></name><name><surname>Huang</surname><given-names>FX</given-names></name></person-group><article-title>Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: A meta-analysis</article-title><source>Diabetologia</source><year>2013</year><volume>56</volume><fpage>457</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">23232641</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohamad Shahi</surname><given-names>M</given-names></name><name><surname>Haidari</surname><given-names>F</given-names></name><name><surname>Shiri</surname><given-names>MR</given-names></name></person-group><article-title>Comparison of effect of resveratrol and vanadium on diabetes related dyslipidemia and hyperglycemia in streptozotocin induced diabetic rats</article-title><source>Adv Pharm Bull</source><year>2011</year><volume>1</volume><fpage>81</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">24312761</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonnalagadda</surname><given-names>VG</given-names></name><name><surname>Ram Raju</surname><given-names>AV</given-names></name><name><surname>Pittala</surname><given-names>S</given-names></name><name><surname>Shaik</surname><given-names>A</given-names></name><name><surname>Selkar</surname><given-names>NA</given-names></name></person-group><article-title>The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus</article-title><source>Adv Pharm Bull</source><year>2014</year><volume>4</volume><fpage>209</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">24754003</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>JE</given-names></name><name><surname>Sicree</surname><given-names>RA</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name></person-group><article-title>Global estimates of the prevalence of diabetes for 2010 and 2030</article-title><source>Diabetes Res Clin Pract</source><year>2010</year><volume>87</volume><fpage>4</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">19896746</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jafari-Shobeiri</surname><given-names>M</given-names></name><name><surname>Ghojazadeh</surname><given-names>M</given-names></name><name><surname>Azami-Aghdash</surname><given-names>S</given-names></name><name><surname>Naghavi-Behzad</surname><given-names>M</given-names></name><name><surname>Piri</surname><given-names>R</given-names></name><name><surname>Pourali-Akbar</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Prevalence and risk factors of gestational diabetes in Iran: A systematic review and meta-analysis</article-title><source>Iran J Public Health</source><year>2015</year><volume>44</volume><fpage>1036</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">26587467</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raparia</surname><given-names>K</given-names></name><name><surname>Usman</surname><given-names>I</given-names></name><name><surname>Kanwar</surname><given-names>YS</given-names></name></person-group><article-title>Renal morphologic lesions reminiscent of diabetic nephropathy</article-title><source>Arch Pathol Lab Med</source><year>2013</year><volume>137</volume><fpage>351</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23451746</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>American Diabetes</surname><given-names>Association</given-names></name></person-group><article-title>Standards of medical care for patients with diabetes mellitus</article-title><source>Puerto Rico Health Sci J</source><year>2013</year><volume>20</volume><fpage>175</fpage><lpage>87</lpage></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tab&#x000e1;k</surname><given-names>AG</given-names></name><name><surname>Herder</surname><given-names>C</given-names></name><name><surname>Rathmann</surname><given-names>W</given-names></name><name><surname>Brunner</surname><given-names>EJ</given-names></name><name><surname>Kivim&#x000e4;ki</surname><given-names>M</given-names></name></person-group><article-title>Prediabetes: A high-risk state for diabetes development</article-title><source>Lancet</source><year>2012</year><volume>379</volume><fpage>2279</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">22683128</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouladsahebmadarek</surname><given-names>E</given-names></name><name><surname>Sayyah-Melli</surname><given-names>M</given-names></name><name><surname>Taghavi</surname><given-names>S</given-names></name><name><surname>Abbasalizadeh</surname><given-names>S</given-names></name><name><surname>Seyedhejazie</surname><given-names>M</given-names></name></person-group><article-title>The effect of supplemental iron elimination on pregnancy outcome</article-title><source>Pak J Med Sci</source><year>2011</year><volume>27</volume><fpage>641</fpage><lpage>5</lpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name><name><surname>Kanasaki</surname><given-names>K</given-names></name></person-group><article-title>Lipid mediators in diabetic nephropathy</article-title><source>Fibrogenesis Tissue Repair</source><year>2014</year><volume>7</volume><fpage>12</fpage><pub-id pub-id-type="pmid">25206927</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghaffari</surname><given-names>MA</given-names></name><name><surname>Askari Sede</surname><given-names>S</given-names></name><name><surname>Rashtchizadeh</surname><given-names>N</given-names></name><name><surname>Mohammadzadeh</surname><given-names>G</given-names></name><name><surname>Majidi</surname><given-names>S</given-names></name></person-group><article-title>Association of CRP gene polymorphism with CRP levels and coronary artery disease in type 2 diabetes in Ahvaz, Southwest of Iran</article-title><source>Bioimpacts</source><year>2014</year><volume>4</volume><fpage>133</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">25337466</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohrabi</surname><given-names>N</given-names></name><name><surname>Shekari Khaniani</surname><given-names>M</given-names></name><name><surname>Mansoori Derakhshan</surname><given-names>S</given-names></name></person-group><article-title>Evaluation of association between HLA class II DR4-DQ8 haplotype and type I diabetes mellitus in children of East Azerbaijan state of Iran</article-title><source>Adv Pharm Bull</source><year>2015</year><volume>5</volume><fpage>137</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">25789232</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbasalizadeh</surname><given-names>F</given-names></name><name><surname>Abbasalizadeh</surname><given-names>S</given-names></name><name><surname>Rashtchizadeh</surname><given-names>N</given-names></name></person-group><article-title>Early diagnosis of preeclampsia by 8 and 12 h urine protein</article-title><source>J Med Sci</source><year>2007</year><volume>7</volume><fpage>551</fpage><lpage>7</lpage></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimmeler</surname><given-names>S</given-names></name><name><surname>Aicher</surname><given-names>A</given-names></name><name><surname>Vasa</surname><given-names>M</given-names></name><name><surname>Mildner-Rihm</surname><given-names>C</given-names></name><name><surname>Adler</surname><given-names>K</given-names></name><name><surname>Tiemann</surname><given-names>M</given-names></name><etal/></person-group><article-title>HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway</article-title><source>J Clin Invest</source><year>2001</year><volume>108</volume><fpage>391</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11489932</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seliger</surname><given-names>SL</given-names></name><name><surname>Weiss</surname><given-names>NS</given-names></name><name><surname>Gillen</surname><given-names>DL</given-names></name><name><surname>Kestenbaum</surname><given-names>B</given-names></name><name><surname>Ball</surname><given-names>A</given-names></name><name><surname>Sherrard</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients</article-title><source>Kidney Int</source><year>2002</year><volume>61</volume><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">11786112</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navaneethan</surname><given-names>SD</given-names></name><name><surname>Pansini</surname><given-names>F</given-names></name><name><surname>Perkovic</surname><given-names>V</given-names></name><name><surname>Manno</surname><given-names>C</given-names></name><name><surname>Pellegrini</surname><given-names>F</given-names></name><name><surname>Johnson</surname><given-names>DW</given-names></name><etal/></person-group><article-title>HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis</article-title><source>Cochrane Database Syst Rev</source><year>2009</year><volume>2</volume><fpage>CD007784</fpage></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behzad</surname><given-names>MN</given-names></name><name><surname>Nezami</surname><given-names>N</given-names></name><name><surname>Piri</surname><given-names>R</given-names></name><name><surname>Safa</surname><given-names>J</given-names></name><name><surname>Salari</surname><given-names>B</given-names></name><name><surname>Zadeh</surname><given-names>NR</given-names></name><etal/></person-group><article-title>Lovastatin enhances paraoxonase enzyme activity and quells low-density lipoprotein susceptibility to oxidation in type 2 diabetic nephropathy</article-title><source>Med J Tabriz Univ Med Sci Health Serv</source><year>2013</year><volume>35</volume><fpage>90</fpage><lpage>7</lpage></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aliasgarzadeh</surname><given-names>A</given-names></name><name><surname>Ghojazadeh</surname><given-names>M</given-names></name><name><surname>Haji-Hoseini</surname><given-names>R</given-names></name><name><surname>Mehanfar</surname><given-names>F</given-names></name><name><surname>Piri</surname><given-names>R</given-names></name><name><surname>Naghavi-Behzad</surname><given-names>M</given-names></name><etal/></person-group><article-title>Age related secretary pattern of growth hormone, insulin-like growth factor-I and insulin-like growth factor binding protein-3 in postmenopausal women</article-title><source>Indian J Med Res</source><year>2014</year><volume>139</volume><fpage>598</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">24927347</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandhu</surname><given-names>S</given-names></name><name><surname>Wiebe</surname><given-names>N</given-names></name><name><surname>Fried</surname><given-names>LF</given-names></name><name><surname>Tonelli</surname><given-names>M</given-names></name></person-group><article-title>Statins for improving renal outcomes: A meta-analysis</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><fpage>2006</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">16762986</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douglas</surname><given-names>K</given-names></name><name><surname>O'Malley</surname><given-names>PG</given-names></name><name><surname>Jackson</surname><given-names>JL</given-names></name></person-group><article-title>Meta-analysis: The effect of statins on albuminuria</article-title><source>Ann Intern Med</source><year>2006</year><volume>145</volume><fpage>117</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">16847294</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Greene</surname><given-names>T</given-names></name><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Hendriksen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate</article-title><source>Ann Intern Med</source><year>2006</year><volume>145</volume><fpage>247</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">16908915</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedewald</surname><given-names>WT</given-names></name><name><surname>Levy</surname><given-names>RI</given-names></name><name><surname>Fredrickson</surname><given-names>DS</given-names></name></person-group><article-title>Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge</article-title><source>Clin Chem</source><year>1972</year><volume>18</volume><fpage>499</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">4337382</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoucri</surname><given-names>RM</given-names></name><name><surname>Pouliot</surname><given-names>M</given-names></name></person-group><article-title>Some observations on the kinetics of the Jaff&#x000e9; reaction for creatinine</article-title><source>Clin Chem</source><year>1977</year><volume>23</volume><fpage>1527</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">890895</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabata</surname><given-names>M</given-names></name><name><surname>Murachi</surname><given-names>T</given-names></name></person-group><article-title>A chemiluminometric method for the determination of urea in serum using a three-enzyme bioreactor</article-title><source>J Biolumin Chemilumin</source><year>1988</year><volume>2</volume><fpage>63</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3213592</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Ushiyama</surname><given-names>C</given-names></name><name><surname>Hirokawa</surname><given-names>K</given-names></name><name><surname>Osada</surname><given-names>S</given-names></name><name><surname>Shimada</surname><given-names>N</given-names></name><name><surname>Koide</surname><given-names>H</given-names></name></person-group><article-title>Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia</article-title><source>Am J Nephrol</source><year>2001</year><volume>21</volume><fpage>449</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">11799261</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonolo</surname><given-names>G</given-names></name><name><surname>Ciccarese</surname><given-names>M</given-names></name><name><surname>Brizzi</surname><given-names>P</given-names></name><name><surname>Puddu</surname><given-names>L</given-names></name><name><surname>Secchi</surname><given-names>G</given-names></name><name><surname>Calvia</surname><given-names>P</given-names></name><etal/></person-group><article-title>Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment</article-title><source>Diabetes Care</source><year>1997</year><volume>20</volume><fpage>1891</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9405913</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atthobari</surname><given-names>J</given-names></name><name><surname>Brantsma</surname><given-names>AH</given-names></name><name><surname>Gansevoort</surname><given-names>RT</given-names></name><name><surname>Visser</surname><given-names>ST</given-names></name><name><surname>Asselbergs</surname><given-names>FW</given-names></name><name><surname>van Gilst</surname><given-names>WH</given-names></name><etal/></person-group><article-title>The effect of statins on urinary albumin excretion and glomerular filtration rate: Results from both a randomized clinical trial and an observational cohort study</article-title><source>Nephrol Dial Transplant</source><year>2006</year><volume>21</volume><fpage>3106</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">16720593</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campese</surname><given-names>VM</given-names></name><name><surname>Park</surname><given-names>J</given-names></name></person-group><article-title>HMG-CoA reductase inhibitors and the kidney</article-title><source>Kidney Int</source><year>2007</year><volume>71</volume><fpage>1215</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">17495867</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>R</given-names></name></person-group><article-title>Statin induced proteinuria: Renal injury or renoprotection?</article-title><source>J Am Soc Nephrol</source><year>2004</year><volume>15</volume><fpage>2502</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">15340001</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fried</surname><given-names>LF</given-names></name><name><surname>Orchard</surname><given-names>TJ</given-names></name><name><surname>Kasiske</surname><given-names>BL</given-names></name></person-group><article-title>Effect of lipid reduction on the progression of renal disease: A meta-analysis</article-title><source>Kidney Int</source><year>2001</year><volume>59</volume><fpage>260</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11135079</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Amico</surname><given-names>G</given-names></name></person-group><article-title>Statins and renal diseases: From primary prevention to renal replacement therapy</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><issue>4 Suppl 2</issue><fpage>S148</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">16565241</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Shimano</surname><given-names>H</given-names></name><name><surname>Yokote</surname><given-names>K</given-names></name><name><surname>Urashima</surname><given-names>M</given-names></name><name><surname>Teramoto</surname><given-names>T</given-names></name></person-group><article-title>Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study</article-title><source>J Atheroscler Thromb</source><year>2010</year><volume>17</volume><fpage>601</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20460830</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorof</surname><given-names>J</given-names></name><name><surname>Berne</surname><given-names>C</given-names></name><name><surname>Siewert-Delle</surname><given-names>A</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>L</given-names></name><name><surname>Sager</surname><given-names>P</given-names></name></person-group><article-title>URANUS Study Investigators. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients</article-title><source>Diabetes Res Clin Pract</source><year>2006</year><volume>72</volume><fpage>81</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16246447</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>R</given-names></name></person-group><article-title>Effects of statins on renal function</article-title><source>Mayo Clin Proc</source><year>2007</year><volume>82</volume><fpage>1381</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">17976359</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenney</surname><given-names>JM</given-names></name><name><surname>Davidson</surname><given-names>MH</given-names></name><name><surname>Jacobson</surname><given-names>TA</given-names></name><name><surname>Guyton</surname><given-names>JR</given-names></name></person-group><article-title>National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force</article-title><source>Am J Cardiol</source><year>2006</year><volume>97</volume><fpage>89C</fpage><lpage>94C</lpage></element-citation></ref></ref-list></back></article>